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Abstract
Backgroud: It has been shown that different symptoms or symptom combinations of neuropathic pain (NeP) may
correspond to different mechanistic backgrounds and respond differently to treatment. The Neuropathic Pain
Symptom Inventory (NPSI) is able to detect distinct clusters of symptoms (i.e. dimensions) with a putative common
mechanistic background. The present study described the psychometric validation of the Portuguese version (PV)
of the NPSI.
Methods: Patients were seen in two consecutive visits, three to four weeks apart. They were asked to: (i) rate their
mean pain intensity in the last 24 hours on an 11-point (0-10) numerical scale; (ii) complete the PV-NPSI; (iii)
provide the list of pain medications and doses currently in use. VAS and Global Impression of Change (GIC) were
filled out in the second visit.
Results: PV-NPSI underwent test-retest reliability, factor analysis, analysis of sensitivity to changes between both
visits. The PV-NPSI was reliable in this setting, with a good intra-class correlation for all items. The factorial analysis
showed that the PV-NPSI inventory assessed different components of neuropathic pain. Five different factors were
found. The PV-NPSI was adequate to evaluate patients with neuropathic pain and to detect clusters of NeP
symptoms.
Conclusions: The psychometric properties of the PV-NPSI rendered it adequate to evaluate patients with both
central and peripheral neuropathic pain syndromes and to detect clusters of NeP symptoms.
Keywords: Neuropathic Pain Symptom Inventory, Portuguese language, neuropathic pain, pain assessment,
questionnaire
Introduction
Neuropathic pain (NeP) probably concerns 7-8% of the
general population [1,2]. In addition to a number of
patients with various neurological diseases [3], NeP
affects significant proportions of patients with diabetes
[4], low back pain [5], post-surgical pain [6], cancer
[7,8] and some infectious diseases [9] and has a major
impact on quality of life.
Neuropathic pain syndromes are rather heterogeneous
and the relationship between a certain etiology and the
symptoms reported by patients are not straightforward.
Different symptoms (i.e., allodynia, burning or paroxys-
mal pain) may coexist in the same patient and may
reflect different mechanisms of disease [10]. Consistent
with this hypothesis, it has been shown that different
symptoms or symptom combinations may respond dif-
ferently to treatment [11-13]. These data highlight the
importance of a specific measurement of neuropathic
pain symptoms or neuropathic components, to assess
the effects of treatment both in clinical trials and in
daily practice.
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Only two questionnaires have been specifically devel-
oped to assess the effects of treatment in neuropathic
pain syndromes [14,15]. To date, the only tool that has
been validated in neuropathic pain syndromes of both
central and peripheral origins is the Neuropathic Pain
Symptom Inventory (NPSI). Also, it is the sole that has
underwent factorial analysis confirming that the quali-
ties of the symptoms measured by this inventory
reflect distinct clusters of symptoms (i.e. dimensions)
with a putative common mechanistic background
[10,15].
Here we validated the translated Portuguese version of
the NPSI (PV-NPSI) [16]. Portuguese is spoken by 240
million people and in the main language in more than
ten countries in America, Europe, Africa and Asia [17].
So far, the NPSI has been translated into more than 60
languages, but its multidimensional structure has only
been confirmed into Italian [18] and Spanish [19].
Methods
After translation of the NPSI from the original French
version and verification of its cultural and conceptual
adequacy in Brazilian patients [16], the psychometric
validation of the Brazilian Portuguese version of the
NPSI was performed in one hundred consecutive
patients with neuropathic pain seen in our outpatient
pain clinic from January to July 2009. The study was
approved by our I nstitution’s Ethics Review Board
(Hospital das Clínicas da Faculdade de Medicina da
Universidade de São Paulo, São Paulo, Brazil), and
written informed consent was obtained from all
participants.
Patients
Inclusion criteria were men and women with chronic
(> 3 months) neuropathic pain of moderate to severe
intensity (> 30 mm on a 100 mm visual analog scale)
of either central or peripheral origin. Neuropathic pain
was diagnosed based on the presence of pain with neu-
ropathic characteristics in the topographic distribution
of a nervous structure [20]. Lesion or disease to the
somatosensory system was confirmed by nerve conduc-
tion tests, magnetic resonance imaging and blood tests
when indicated. Exclusion criteria were: the presence
of major depression, alcohol abuse as assessed by the
CAGE questionnaire [21], the presence of an other
pain of clear non neuropathic origins (e.g. myofascial
pain syndrome) [22], instances where the lesion to the
somatosensory system could no be clearly detected
(complex regional pain syndrome) [23] and pain syn-
dromes of clear mixed origins (failed back surgery syn-
drome, tumor-related pain), low level of education
(less than eight years) and non Portuguese-native
speakers.
Study Design
Patients were seen in two consecutive visits, three to
four weeks apart. In the first visit, before the regular
consultation, they were invited to participate in the
study protocol and gave their informed consent. Name,
age, neuropathic pain diagnosis and associated disorders
were recorded, as well as pain symptoms duration. Then
they were asked to: (i) rate their mean pain intensity in
the last 24 hours on an 11-point (0-10) numerical scale;
(ii) complete the PV-NPSI; (iii) provide the list of pain
medications and doses currently in use. Pain medication
and dosing were quantified according to the Medication
Quantification Score (MQS) [24]. In the second visit,
patients were asked to rate the intensity of their pain on
an 11-point scale, to fill out the PV-NPSI and to rate
the global evolution of their pain since the first visit by
the Patient Global Impression of Change (p-GIC). The
evaluator also rated the global evolution of the pain by
the Clinical Global Impression of Change (c-GIC). In
both cases, the GIC included seven ranks ranging from
1 to 7 (1 = very much improved, 2 = moderately
improved, 3 = slightly improved, 4 = no change; 5 =
slightly aggravated; 6 = moderately aggravated; 7 = very
much aggravated). The number of patients included in
the study was calculated from the total number of items
of the PV-NPSI that would undergo factorial analyses
[25] and from the original NPSI publication [15].
Assessment of the psychometrics properties of the PV-
NPSI
Assessment of test-retest reliability
The test-retest reliability of each item and the score of
the PV-NPSI was assessed using the Intraclass coeffi-
cient (ICC) calculated by the estimation of components
by analysis of variance [26]. Long-term reliability was
evaluated by comparing the PV-NPSI scores and sub
scores in patients who did not show any change in their
pain during both visits (i.e: score 4 - no change; on the
p-CGC in the second visit).
Factor Analysis
An exploratory factor analysis was performed using the
principal component analysis as the method of extrac-
tion. The Catell Scree test was used for determining the
number of factors extracted. Independent factors were
obtained using the Varimax rotation method.
Convergent validity
Correlations between changes in pain intensity on the
11-point numeric scale and the changes in the PV-NPSI
total score and sub scores were evaluated by the Spear-
man’s correlation coefficient.
Analysis of sensitivity to changes between both visits
The correlation between the subjective evaluation by
patients (p-GIC) in the second visit and the change in
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the PV-NPSI score and sub scores were assessed by the
Spearman’s Correlation Coefficient.
Results
Clinical features
Ninety-four patients were included in the study. Six
failed to come to the second visit within the study inter-
val due to personal reasons. Patient’s clinical characteris-
tics and pain etiology are expressed in Table 1.
Face validity
The PV-NPSI was filled out in less than 8 minutes by
85% of the patients. It took less than 12 minutes in the
remaining. The “prevalence” (i.e. percentage of patients
reporting a score > 0) in the majority of items was 65%
(table 2).
Test-retest validity
Thirty patients did not present any change in their pain
between both visits (ie. p-GIC). The NPSI scores of
these patients were retained to evaluate the test-retest
reliability of the PV-NPSI (table 3).
Factor analysis
The factor analysis identified a five-factor solution,
which accounted for 71% of the total variance. Most
items had high loadings on only one factor (Table 4).
Each of the five factors corresponded to a relevant
clinical component of neuropathic pain. Factor 1
included the three items related to evoked pain (i.e. pain
evoked by brushing, pressure or contact with cold) and
two spontaneous pain items (squeezing and pressure).
Factor 2 included two items (i.e. stabbing and pins and
needles), which might correspond to the paroxysmal
component of spontaneous pain. Factor 3 included tin-
gling (corresponding to the abnormal sensations). Factor
4 included one item (burning) corresponding to superfi-
cial component of ongoing pain frequently observed in
neuropathic pain syndromes. Finally, factor 5 included
only one item (electric shocks) corresponded to clear
paroxysmal pain.
Convergent analysis
The total score of the questionnaire (1st and 2nd visits)
correlated with the numerical rating scale measured in
each visit (Spearman correlation = 0.40; p < 0.0001; and
0.53; p < 0.0001; respectively). However, the change in
the PV-NPSI score between both visits (PV-NPSI visit 2
- PV-NPSI visit 1) only weakly correlated with the
change in the visual numeric scale between both visits
(2nd score - 1st score) (Spearman correlation = 0.22).
The change in the PV-NPSI score between both visits
Table 1 Main clinical characteristics of patients included
in the study.
Clinical and demographic data
Age 52.6 ± 14.9 (27-84)
Sex (women/men) 37/57
Mean duration of pain (months) 51.7 ± 21.4 (6-120)
Mean pain intensity (VAS) 6.7 ± 2.0 (4-10)
Mean MQS 10.1 ± 5.3 (1.0-25.0)
Aetiology of neuropathic pain
Nerve trauma 15 (15.9%)
Post herpetic neuralgia 20 (21.3%)
Diabetic polyneuropathy 6 (6.4%)
Non-diabetic polyneuropathy 5 (5.3%)
Post-stroke pain 4 (4.2%)
Spinal cord trauma 9 (9.5%)
Plexus avulsion 19 (20.2%)
Trigeminal neuralgia 4 (4.25%)
Syringomyelia 2 (2.1%)
Leprosy associated neuropathic pain 10 (10.6%)
Medication use
Medication Quantification Score 10.14 ± 5.96
Results are expressed in average ± standard deviation (range).
Table 2 Frequency of items reported as > 1.
Pain Descriptor
(items)
Percentage of patients who reported a
score > 0
Burning 73.4%
Squeezing 57.4%
Pressure 56.3%
Electric shocks (5) 65.9%
Stabbing 47.9%
Evoked by brushing 64.8%
Evoked by pressure
(8)
60.6%
Evoked by cold
stimulus
63.8%
Pins and needles 68.0%
Tingling 81.9%
Table 3 Interclass Correlation Coefficient between of
each PV-NPSI item in both visits.
Test-retest reliability
Burning 0.9294
Pressure 0.9450
Squeezing 0.9664
Electric shocks 0.9309
Stabbing 0.9365
Pain evoked by brushing 0.6633
Pin evoked by pressure 0.7844
Pain evoked by cold stimuli 0.7820
Pins and needles 0.7596
Tingling 0.6280
Total Score 0.7678
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did not significantly correlate with pain duration or
medication use (MQS).
Sensitivity to change
The p-GIC and c-GIC scores at the second visit strongly
correlated (rho = 0.727; rho = 0.645, respectively) with
the change in the PV-NPSI score between the two visits
(PV-NPSI visit 2 - PV-NPSI visit 1) (Figure 1).
The p-GIC and c-GIC scores at the second visit mod-
erately correlated (rho = 0.446, 0.440) with the change
in the visual numeric scale score between both visits
(VNS from 2nd visit - VNS from 1st visit).
Discussion
Neuropathic pain is common [27], and its prevalence
in certain populations of patients is particularly high,
such as in diabetics, cancer, and HIV patients [8,28].
Different screening tools have been proposed to iden-
tify patients with a higher probability to present neu-
ropathic pain, such as the LANSS [29,30] and the
DN-4 [2]. These tools have been translated and vali-
dated in different languages and are used broadly in
clinical trials and epidemiological studies [7,31]. Only
two scales were specifically created and validated to
assess neuropathic pain syndromes [14,15]. The NPSI
is the only tool validated in patients with neuropathic
pain of central and peripheral origin and has a factor-
ial design validated in a broad range neuropathic pain
patients.
The present study described the psychometric valida-
tion of the Portuguese version of the NPSI. The valida-
tion process showed that the present version of the self-
questionnaire is: (i) valid and reliable; (ii) it is sensitive
to changes in neuropathic pain of both central and per-
ipheral origin; and (iii) it assessed different aspects of
neuropathic pain.
Table 4 Rotated factor loadings and communalities:
Varimax Rotation.
Variable Factor1 Factor
2
Factor
3
Factor
4
Factor
5
Communality
Q1 -0.083 0.032 0.037 -0.929 0.050 0.875
Q2 0.538 -0.165 -0.510 -0.369 0.061 0.716
Q3 0.607 0.226 -0.427 0.091 -0.370 0.747
Q5 0.229 0.145 -0.200 -0.066 0.831 0.809
Q6 0.324 0.774 0.048 -0.108 -0.042 0.721
Q8 0.776 0.095 0.155 -0.123 0.166 0.678
Q9 0.589 0.337 -0.101 0.128 0.049 0.489
Q10 0.651 0.132 0.037 0.283 0.333 0.634
Q11 0.032 0.759 -0.199 0.073 0.191 0.658
Q12 -0.096 0.163 -0.837 0.071 0.178 0.773
Variance 2.2054 1.4420 1.2622 1.1451 1.0447 7.0994
% Var 0.221 0.144 0.126 0.115 0.104 0.710
Factor 1 Q2 Q3 Q8 Q9 Q10
Factor 2 Q6 Q11
Factor 3 Q12
Factor 4 Q1
Factor 5 Q5
Figure 1 Correlation between the GIC-p scores at the second visit and the change in the PV-NPSI score between the two visits (PV-
NPSI visit 2 - PV-NPSI visit 1) (rho = 0.727).
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The PV-NPSI was filled out in a relatively short period
of time making it suitable for the use in clinical practice
and in clinical studies. All descriptors were reported in
a significant frequency of patients, with a prevalence of
65%. We assessed the test-retest validity of the inventory
in those patients who did not present any change in
their pain intensity between both visits. The PV-NPSI
was reliable in this setting, with a good intraclass corre-
lation for all items.
The total score of the PV-NPSI in the 1st and 2nd vis-
its correlated with the visual numeric scale score in
each of these sessions. However, the change in the PV-
NPSI from the 2nd to the 1st visit only weakly correlated
to the changes in the VNS score between both
instances. This is similar to what was found in the origi-
nal version of the NPSI [15]. Interestingly, GIC scores in
the second visit showed a high correlation with the
change in the PV-NPSI between both visits, while the
change in the VNS score only moderately correlated
with the GIC scores. This attests that in this population
of neuropathic pain patients, the total score of the PV-
NPSI was better suited to assess neuropathic pain char-
acteristics than the VNS score, showing good validity
and reliability.
The factorial analysis showed that the PV-NPSI
assessed different components of neuropathic pain. Five
different factors were found. The first factor included
evoked pain (i.e. pain evoked by brushing, pressure or
contact with cold) and two spontaneous pain descriptors
(squeezing and pressure). Two paroxysmal descriptors
(stabbing and pins and needles) were clustered in a sec-
ond factor. The three remaining descriptors were
grouped in one factor each (burning pain, electric
shocks and tingling). Some of the cluster patterns were
slightly different from the original version where sponta-
neous pain and paroxysmal descriptors were clustered in
a single factor each. These differences probably reflect
different valences of each descriptor between the two
populations [15].
Neuropathic pain is a rather heterogeneous entity and
different symptoms may be caused by a single etiological
factor, thus suggesting it is a “trans-etiological” entity
[10]. Neuropathic pain symptoms are thought to reflect
specific pain mechanisms. Two main approaches have
employed questionnaires based on pain characteristics
to broaden our knowledge on this topic. One used these
tools to gain mechanistic insights on this pain syn-
drome. For example, it has been shown that the inten-
sity of ongoing pain, as detected by the NPSI inversely
correlated to the amplitude of laser evoked potentials in
patients with painful distal polyneuropathy, suggesting
that damage to intra-epidermal nociceptive terminals
would be implicated in this specific symptom of NeP
[32]. In another study, it has been shown that patients
presenting exclusively with spontaneous pain according
to the NPSI significantly differed from those also pre-
senting with evoked pain. Isolated spontaneous pain was
highly correlated with a greater decrease in white matter
tract metrics seen under tractography, suggesting a
more intense injury to the somatosensory system. Also,
the presence of evoked pain in the NPSI was associated
with a more discrete spinothalamic dysfunction as
assessed by laser-evoked potentials when compared to
patients without this pain symptom [33]. This supports
the idea that different aspects of neuropathic pain as
assessed by the NPSI are associated with different anato-
mical dysfunctions and pathophysiological backgrounds
in patients with NeP. Another use of these tools was to
to guide mechanism-based approaches to NeP treat-
ment, since it has been increasingly shown that the effi-
cacy of pharmacological treatment may vary depending
on the presence of certain symptoms (mechanisms) of
neuropathic pain [12,34,35].
In conclusion, the psychometric properties of the PV-
NPSI render it adequate to evaluate patients with both
central and peripheral neuropathic pain syndromes. The
reliability of the different descriptors was adequate and
sensitive to change and the NPSI may help select sub-
groups of NeP patients with different anatomical and
mechanistic dysfunctions, and possibly different
response to treatment.
Author details
1Pain Center, Hospital das Clínicas, Department of Neurology of the
University of São Paulo, Brazil. 2Instituto do Câncer do Estado de São Paulo
Otávio Frias de Oliveira, Brazil. 3Divisão de Neurologia e Epidemiologia,
Universidade Federal da Bahia, Brazil. 4Coordenação de Pós-Graduação,
Pesquisa e Extensão, Escola Bahiana de Medicina e Saúde Pública, Brazil.
5INSERM U-987, CHU Ambroise Paré, APHP, F-92100 Boulogne-Billancourt,
France.
Authors’ contributions
Study Design: DCA, DB, MJT. Data Collection: CMN, AFB, LTY, JA, PRNS,
HelenaHK, KS. Data bank feeding: TZ, RG. Statistical analyses: DCA, ETF.
Manuscript writing: DCA, KASLF. Manuscript revising: DB, MJT. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 11 July 2011 Accepted: 30 November 2011
Published: 30 November 2011
References
1. Bennett M: The LANSS Pain Scale: the Leeds assessment of neuropathic
symptoms and signs. Pain 2001, 92(1-2):147-157.
2. Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C: Prevalence of
chronic pain with neuropathic characteristics in the general population.
Pain 2008, 136(3):380-387.
3. Martinez V, Fletcher D, Martin F, Orlikowski D, Sharshar T, Chauvin M,
Bouhassira D, Attal N: Small fibre impairment predicts neuropathic pain
in Guillain-Barre syndrome. Pain 2010, 151(1):53-60.
4. Jensen MP, Friedman M, Bonzo D, Richards P: The validity of the
neuropathic pain scale for assessing diabetic neuropathic pain in a
clinical trial. Clin J Pain 2006, 22(1):97-103.
de Andrade et al. Health and Quality of Life Outcomes 2011, 9:107
http://www.hqlo.com/content/9/1/107
Page 5 of 6
5. Kaki AM, El-Yaski AZ, Youseif E: Identifying neuropathic pain among
patients with chronic low-back pain: use of the Leeds Assessment of
Neuropathic Symptoms and Signs pain scale. Reg Anesth Pain Med 2005,
30(5):422-428.
6. Martinez V, Fletcher D, Bouhassira D, Sessler DI, Chauvin M: The evolution
of primary hyperalgesia in orthopedic surgery: quantitative sensory
testing and clinical evaluation before and after total knee arthroplasty.
Anesth Analg 2007, 105(3):815-821.
7. Kerba M, Wu JS, Duan Q, Hagen NA, Bennett MI: Neuropathic Pain
Features in Patients With Bone Metastases Referred for Palliative
Radiotherapy. J Clin Oncol 2010.
8. Attal N, Bouhassira D, Gautron M, Vaillant JN, Mitry E, Lepere C, Rougier P,
Guirimand F: Thermal hyperalgesia as a marker of oxaliplatin
neurotoxicity: a prospective quantified sensory assessment study. Pain
2009, 144(3):245-252.
9. de Andrade DC, Jean S, Clavelou P, Dallel R, Bouhassira D: Chronic pain
associated with the Chikungunya Fever: long lasting burden of an acute
illness. BMC Infect Dis 2010, 10:31.
10. Attal N, Fermanian C, Fermanian J, Lanteri-Minet M, Alchaar H, Bouhassira D:
Neuropathic pain: are there distinct subtypes depending on the
aetiology or anatomical lesion? Pain 2008, 138(2):343-353.
11. Attal N, Guirimand F, Brasseur L, Gaude V, Chauvin M, Bouhassira D: Effects
of IV morphine in central pain: a randomized placebo-controlled study.
Neurology 2002, 58(4):554-563.
12. Attal N, Gaude V, Brasseur L, Dupuy M, Guirimand F, Parker F, Bouhassira D:
Intravenous lidocaine in central pain: a double-blind, placebo-controlled,
psychophysical study. Neurology 2000, 54(3):564-574.
13. Attal N, Brasseur L, Parker F, Chauvin M, Bouhassira D: Effects of
gabapentin on the different components of peripheral and central
neuropathic pain syndromes: a pilot study. Eur Neurol 1998, 40(4):191-200.
14. Galer BS, Jensen MP: Development and preliminary validation of a pain
measure specific to neuropathic pain: the Neuropathic Pain Scale.
Neurology 1997, 48(2):332-338.
15. Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E,
Rostaing S, Lanteri-Minet M, Collin E, Grisart J, et al: Development and
validation of the Neuropathic Pain Symptom Inventory. Pain 2004,
108(3):248-257.
16. Crawford B, Bouhassira D, Wong A, Dukes E: Conceptual adequacy of the
neuropathic pain symptom inventory in six countries. Health Qual Life
Outcomes 2008, 6:62.
17. Gordon RG Jr: Portuguese. Ethnologue: Languages of the World. SIL
International;, 15 20051.
18. Padua L, Briani C, Jann S, Nobile-Orazio E, Pazzaglia C, Morini A, Mondelli M,
Ciaramitaro P, Cavaletti G, Cocito D, et al: Validation of the Italian version
of the Neuropathic Pain Symptom Inventory in peripheral nervous
system diseases. Neurol Sci 2009, 30(2):99-106.
19. Villoria J, Rodríguez M, Berro MJ, Stern A, Sánchez-Magro I: Psychometric
Validation of the neuropathic pain symptom inventory for its use in
Spanish. J Pain Symptom Manage 2011, 42(1):134-46.
20. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW,
Hansson P, Hughes R, Nurmikko T, Serra J: Neuropathic pain: redefinition
and a grading system for clinical and research purposes. Neurology 2008,
70(18):1630-1635.
21. Ewing JA: Detecting alcoholism. The CAGE questionnaire. JAMA 1984,
252(14):1905-1907.
22. Simons DG: Review of enigmatic MTrPs as a common cause of enigmatic
musculoskeletal pain and dysfunction. J Electromyogr Kinesiol 2004,
14(1):95-107.
23. Justins DM: Complex Regional Pain Syndrome. Seattle: IASP Scientific
Program Committee (11th World Congress on Pain); 2005.
24. Masters Steedman S, Middaugh SJ, Kee WG, Carson DS, Harden RN,
Miller MC: Chronic-pain medications: equivalence levels and method of
quantifying usage. Clin J Pain 1992, 8(3):204-214.
25. Kachigan SK: Multivariate statistical analysis: a conceptual introduction.
New york: Radius Press;, 2 1991.
26. Muller R, Buttner P: A critical discussion of intraclass correlation
coefficients. Stat Med 1994, 13(23-24):2465-2476.
27. Torrance N, Smith BH, Bennett MI, Lee AJ: The epidemiology of chronic
pain of predominantly neuropathic origin. Results from a general
population survey. J Pain 2006, 7(4):281-289.
28. Potter J, Higginson IJ, Scadding JW, Quigley C: Identifying neuropathic
pain in patients with head and neck cancer: use of the Leeds
Assessment of Neuropathic Symptoms and Signs Scale. J R Soc Med
2003, 96(8):379-383.
29. Perez C, Galvez R, Insausti J, Bennett M, Ruiz M, Rejas J: [Linguistic
adaptation and Spanish validation of the LANSS (Leeds Assessment of
Neuropathic Symptoms and Signs) scale for the diagnosis of
neuropathic pain]. Med Clin (Barc) 2006, 127(13):485-491.
30. Yucel A, Senocak M, Kocasoy Orhan E, Cimen A, Ertas M: Results of the
Leeds assessment of neuropathic symptoms and signs pain scale in
Turkey: a validation study. J Pain 2004, 5(8):427-432.
31. Santos JG, Brito JO, Andrade DCd, Kaziyama VM, Ferreira KA, Souza I,
Teixeira MJ, Bouhassira D, Baptista AF: Translation to Portuguese and
Validation of the Douleur Neuropathique 4 Questionnaire. The Journal of
Pain 2010, 11(5):484-490.
32. Truini A, Biasiotta A, La Cesa S, Di Stefano G, Galeotti F, Petrucci MT,
Inghilleri M, Cartoni C, Pergolini M, Cruccu G: Mechanisms of pain in distal
symmetric polyneuropathy: a combined clinical and neurophysiological
study. Pain 2010, 150(3):516-521.
33. Hatem SM, Attal N, Ducreux D, Gautron M, Parker F, Plaghki L, Bouhassira D:
Clinical, functional and structural determinants of central pain in
syringomyelia. Brain 2010, 133(11):3409-3422.
34. Eisenberg E, Midbari A, Haddad M, Pud D: Predicting the analgesic effect
to oxycodone by ‘static’ and ‘dynamic’ quantitative sensory testing in
healthy subjects. Pain 2010, 151(1):104-109.
35. Finnerup NB, Sindrup SH, Bach FW, Johannesen IL, Jensen TS: Lamotrigine
in spinal cord injury pain: a randomized controlled trial. Pain 2002,
96(3):375-383.
doi:10.1186/1477-7525-9-107
Cite this article as: de Andrade et al.: Psychometric validation of the
Portuguese version of the Neuropathic Pain Symptoms Inventory.
Health and Quality of Life Outcomes 2011 9:107.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
de Andrade et al. Health and Quality of Life Outcomes 2011, 9:107
http://www.hqlo.com/content/9/1/107
Page 6 of 6
